Who are AllerT low dose's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): House dust mite Novo Helisen Depot, tree 12 SQ-Bet, Cupressus arizonica, GRASS 2800 BAU, AllerT, AIT Tablet.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/allert-low-dose.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

AllerT low dose — Competitive Intelligence Brief

AllerT low dose (AllerT low dose) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Allergen immunotherapy. Area: Immunology / Allergy.

phase 2 Allergen immunotherapy Immunology / Allergy Small molecule Live · refreshed every 30 min

Target snapshot

AllerT low dose (AllerT low dose) — Anergis. AllerT is an allergen immunotherapy designed to induce immune tolerance to allergens through low-dose, modified allergen exposure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
AllerT low dose TARGET	AllerT low dose	Anergis	phase 2	Allergen immunotherapy
House dust mite Novo Helisen Depot	House dust mite Novo Helisen Depot	Allergopharma GmbH & Co. KG	marketed	Allergen immunotherapy
tree 12 SQ-Bet	tree 12 SQ-Bet	Clinique Spécialisée en Allergies de la Capitale	marketed	Allergen immunotherapy (sublingual tablet)	Tree pollen allergens (IgE cross-linking epitopes)
Cupressus arizonica	Cupressus arizonica	Laboratorios Leti, S.L.	marketed	Allergen immunotherapy
GRASS 2800 BAU	GRASS 2800 BAU	Clinique Spécialisée en Allergies de la Capitale	marketed	Allergen immunotherapy extract	Grass pollen allergens (Poa pratensis, Lolium perenne, and other grass species)
AllerT	AllerT	Anergis	marketed	Allergen immunotherapy (peptide-based)	Allergen-derived peptide epitopes
AIT Tablet	AIT Tablet	ALK-Abelló A/S	marketed	Allergen immunotherapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Allergen immunotherapy class)

Allergopharma GmbH & Co. KG · 8 drugs in this class
HAL Allergy · 2 drugs in this class
Medical University of Silesia · 2 drugs in this class
ALK-Abelló A/S · 2 drugs in this class
Laboratorios Leti, S.L. · 1 drug in this class
National Taiwan University Hospital · 1 drug in this class
Royal Sussex County Hospital · 1 drug in this class
The University of Texas Medical Branch, Galveston · 1 drug in this class
University of Genova · 1 drug in this class
Anergis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AllerT low dose — Competitive Intelligence Brief. https://druglandscape.com/ci/allert-low-dose. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab